[Targeted therapy of dermatofibrosarcoma with imatinib].
Ugurel
Selma
S
Klinische Kooperationseinheit Dermato-Onkologie, Deutsches Krebsforschungszentrum Heidelberg, Universitäts-Hautklinik Mannheim, Mannheim, Germany. s.ugurel@dkfz.de
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D002869:Chromosome Aberrations; D017322:Clinical Trials, Phase II as Topic; D018223:Dermatofibrosarcoma / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality; D018572:Disease-Free Survival; D016503:Drug Delivery Systems / Q000379:methods*; D005260:Female; D015321:Gene Rearrangement; D006801:Humans; D000068877:Imatinib Mesylate; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D020797:Receptor, Platelet-Derived Growth Factor beta / Q000235:genetics; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D020797:Receptor, Platelet-Derived Growth Factor beta